NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

The National Comprehensive Cancer Network has updated its guidelines for genetic testing to assess the risk of breast, ovarian and pancreatic cancer.

“These NCCN guidelines still have a strong focus on BRCA1 and [BRCA]2 mutations, but also now include other high- and moderate-penetrance genes associated with breast, ovarian, and pancreatic cancer,” Mary Daly from Fox Chase Cancer Center and the chair of the guidelines panel said in a statement.

The NCCN recommends genetic testing for all pancreatic cancer patients, but now, updated criteria include greater recognition of genetic risks associated with pancreatic cancer, and mention the cancer in the guideline title. The update includes more information on the genes associated with pancreatic cancer and what screening or management approaches clinicians should take if individuals have pathogenic or likely pathogenic mutations in these genes.

Source: https://www.genomeweb.com/molecular-diagnostics/nccn-updates-genetic-testing-guidelines-assessing-breast-ovarian-pancreatic